Eliem Therapeutics (NASDAQ:ELYM) Shares Down 3.5% – Should You Sell?

Eliem Therapeutics, Inc. (NASDAQ:ELYM) shares dropped 3.5% on Friday. The stock traded as low as $11.03 and last traded at $11.07. 953,156 shares were traded during trading, an increase of 96% from the average session volume of 486,688 shares. The stock had previously closed at $11.47.

Eliem Therapeutics Stock Down 3.5%

The stock has a fifty day moving average of $14.16 and a 200-day moving average of $11.68. The stock has a market cap of $329.35 million, a PE ratio of -20.89 and a beta of -0.39.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc is a biotechnology company focused on developing therapies for disorders of the nervous system. Its research has centered on treatments for neurological and psychiatric conditions, including pain, epilepsy, depression and other diseases involving the central and peripheral nervous systems.

The company’s former development programs included ETX-155, an investigational neurosteroid intended to modulate GABA-A receptors for potential use in depressive disorders, and ETX-810, a prodrug candidate designed to address neuropathic pain and related conditions.